Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma

(2019) Maria Cucè et al.   Journal of Hematology & Oncology

Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It

(2019) Donatella Aldinucci et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The role of necroptosis in cancer biology and therapy

(2019) Yitao Gong et al.   Molecular Cancer

Trabectedin reveals a strategy of immunomodulation in chronic lymphocytic leukemia

(2019) Priyanka Banerjee et al.   Cancer Immunology Research

Fibroblasts in Nodular Sclerosing Classical Hodgkin Lymphoma Are Defined by a Specific Phenotype and Protect Tumor Cells from Brentuximab-Vedotin Induced Injury

(2019) Katrin Bankov et al.   Cancers

Enriching cancer pharmacology with drugs of marine origin

(2019) Paula C. Jimenez et al.   BRITISH JOURNAL OF PHARMACOLOGY

High CD206 levels in Hodgkin lymphoma‐educated macrophages are linked to matrix‐remodeling and lymphoma dissemination

(2019) Annekatrin Arlt et al.   Molecular Oncology

Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management

(2018) Stephen M. Ansell   AMERICAN JOURNAL OF HEMATOLOGY

Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients

(2018) Neha Mehta-Shah et al.   BLOOD

Mass cytometry of Hodgkin lymphoma reveals a CD4+exhausted T-effector and T-regulatory cell rich microenvironment

(2018) Fathima Zumla Cader et al.   BLOOD

Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma

(2018) Filippo Spriano et al.   BRITISH JOURNAL OF HAEMATOLOGY

Hodgkin Lymphoma-Derived Extracellular Vesicles Change the Secretome of Fibroblasts Toward a CAF Phenotype

(2018) Bastian Dörsam et al.   Frontiers in Immunology

Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model

(2018) Tasuku Kiyuna et al.   BMC CANCER

Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma

(2018) Laura Carminati et al.   CARCINOGENESIS

Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530

(2018) Silvia L. Locatelli et al.   CLINICAL CANCER RESEARCH

CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth

(2018) Naike Casagrande et al.   HAEMATOLOGICA

The efficacy of trabectedin in treating ovarian cancer

(2017) Eleonora Teplinsky et al.   EXPERT OPINION ON PHARMACOTHERAPY

Tumour-associated macrophages as treatment targets in oncology

(2017) Alberto Mantovani et al.   Nature Reviews Clinical Oncology

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells

(2017) Marco Ruella et al.   Cancer Discovery

Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma

(2017) Frederik Wein et al.   Cancer Immunology Research

Systemic Therapy in Metastatic or Unresectable Well-Differentiated/Dedifferentiated Liposarcoma

(2017) Yevette McGovern et al.   Frontiers in Oncology

Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance

(2016) Donatella Aldinucci et al.   CANCER LETTERS

Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma

(2016) Manuel Gotti et al.   HEMATOLOGICAL ONCOLOGY

Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia

(2016) G Lohmann et al.   LEUKEMIA

A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia

(2016) L Mannarino et al.   PHARMACOGENOMICS JOURNAL

Unique features of trabectedin mechanism of action

(2015) Annette K. Larsen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients

(2015) Tamar Tadmor et al.   MAYO CLINIC PROCEEDINGS

Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study

(2014) Ji-Young Choe et al.   BMC CANCER

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment

(2014) M D’Incalci et al.   BRITISH JOURNAL OF CANCER

Macrophages and Dendritic Cells as Actors in the Immune Reaction of Classical Hodgkin Lymphoma

(2014) Christiane Silke Tudor et al.   PLoS One

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

(2013) Giovanni Germano et al.   CANCER CELL

Necroptosis: The Release of Damage-Associated Molecular Patterns and Its Physiological Relevance

(2013) Agnieszka Kaczmarek et al.   IMMUNITY

Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols

(2012) Wesley Greaves et al.   Journal of Hematology & Oncology

Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome

(2010) C. Steidl et al.   BLOOD

Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma

(2010) Christian Steidl et al.   NEW ENGLAND JOURNAL OF MEDICINE

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model

(2009) A. Di Stasi et al.   BLOOD

Expression of CCR5 receptors on Reed–Sternberg cells and Hodgkin lymphoma cell lines: Involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions

(2007) Donatella Aldinucci et al.   INTERNATIONAL JOURNAL OF CANCER